Pacific Biosciences of California, Inc. (PACB) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 57.95M USD | Gross Profit |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $57.95M | (m) | (m) | (m) |
| 2026-03-31 | $59.99M | (m) | (m) | (m) |
| 2025-12-31 | $45.78M | (m) | (m) | (m) |
| 2025-09-30 | $39.27M | (m) | (m) | (m) |
| 2025-06-30 | $33.38M | (m) | (m) | (m) |
| 2025-03-31 | $24.63M | (m) | (m) | (m) |
| 2024-12-31 | $37.28M | (m) | (m) | (m) |
| 2024-09-30 | $36.80M | (m) | (m) | (m) |
| 2024-06-30 | $44.69M | (m) | (m) | (m) |
| 2024-03-31 | $54.30M | (m) | (m) | (m) |
| 2023-12-31 | $52.78M | (m) | (m) | (m) |
| 2023-09-30 | $48.35M | (m) | (m) | (m) |
| 2023-06-30 | $43.99M | (m) | (m) | (m) |
| 2023-03-31 | $44.64M | (m) | (m) | (m) |
| 2022-12-31 | $49.03M | (m) | (m) | (m) |
| 2022-09-30 | $60.66M | (m) | (m) | (m) |
| 2022-06-30 | $62.48M | (m) | (m) | (m) |
| 2022-03-31 | $60.04M | (m) | (m) | (m) |
| 2021-12-31 | $58.86M | (m) | (m) | (m) |
| 2021-09-30 | $53.49M | (m) | $68.14M | (m) |
| 2021-06-30 | $45.20M | (m) | $60.63M | (m) |
| 2021-03-31 | $38.05M | (m) | $54.24M | (m) |
| 2020-12-31 | $32.57M | (m) | $46.33M | (m) |
| 2020-09-30 | $34.10M | (m) | $45.59M | (m) |
| 2020-06-30 | $33.95M | (m) | $48.57M | (m) |
| 2020-03-31 | $36.95M | (m) | $53.12M | (m) |
| 2019-12-31 | $34.58M | (m) | $56.31M | (m) |
| 2019-09-30 | $27.39M | $82.49M | $55.10M | 33.21% |
| 2019-06-30 | $23.67M | $78.73M | $55.06M | 30.06% |
| 2019-03-31 | $22.92M | $75.69M | $52.77M | 30.28% |
| 2018-12-31 | $25.10M | $78.63M | $53.53M | 31.92% |
| 2018-09-30 | $28.84M | $84.03M | (m) | 34.32% |
| 2018-06-30 | $33.88M | $89.42M | (m) | 37.89% |
| 2018-03-31 | $33.02M | $87.92M | (m) | 37.56% |
| 2017-12-31 | $34.66M | $93.47M | (m) | 37.08% |
| 2017-09-30 | $36.54M | $94.25M | (m) | 38.77% |
| 2017-06-30 | $40.95M | $95.83M | (m) | 42.73% |
| 2017-03-31 | $43.59M | $96.50M | (m) | 45.17% |
| 2016-12-31 | $44.16M | $90.71M | (m) | 48.68% |
| 2016-09-30 | $59.25M | $101.27M | (m) | 58.51% |
| 2016-06-30 | $53.16M | $90.07M | (m) | 59.03% |
| 2016-03-31 | $57.03M | $94.26M | (m) | 60.50% |
| 2015-12-31 | $53.45M | $92.78M | (m) | 57.61% |
| 2015-09-30 | $31.42M | $73.41M | (m) | 42.81% |
| 2015-06-30 | $38.03M | $80.11M | (m) | 47.48% |
| 2015-03-31 | $26.65M | $66.60M | (m) | 40.02% |
| 2014-12-31 | $23.40M | $60.59M | (m) | 38.62% |
| 2014-09-30 | $22.15M | $52.82M | (m) | 41.94% |
| 2014-06-30 | $10.23M | $39.62M | (m) | 25.82% |
| 2014-03-31 | $8.16M | $34.24M | (m) | 23.84% |
| 2013-12-31 | $6.42M | $28.18M | (m) | 22.78% |
| 2013-09-30 | $3.86M | $24.93M | (m) | 15.47% |
| 2013-06-30 | $2.81M | $20.28M | (m) | 13.84% |
| 2013-03-31 | $2.02M | $21.52M | (m) | 9.39% |
| 2012-12-31 | $940.00K | $25.98M | (m) | 3.62% |
| 2012-09-30 | $1.85M | $32.55M | (m) | 5.68% |
| 2012-06-30 | $4.99M | $40.29M | (m) | 12.38% |
| 2012-03-31 | $12.61M | $43.63M | (m) | 28.91% |
| 2011-12-31 | $13.03M | $33.86M | (m) | 38.49% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.67M | $1.67M | (m) | 100.00% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $135.00K | $135.00K | (m) | 100.00% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |